Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
GEN-3017 by Genmab for T-Cell Lymphomas: Likelihood of Approval
GEN-3017 is under clinical development by Genmab and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II...
Data Insights
GEN-3017 by Genmab for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
GEN-3017 is under clinical development by Genmab and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...